In this article published in BioProcess International, CRA’s Brian Carpenter, Robert Broadnax, and Andrew Thomson discuss how although the microbiome sector holds significant promise, manufacturers face three key challenges in the clinical development and commercialization of microbiome-based therapeutics.
Microbiome-based therapeutics have evolved significantly in recent years, with several promising candidates advancing through the clinical pipeline. That progress is the result of growing evidence showing that targeting and manipulating the microbiome could improve human health and treat more than 25 conditions by restoring healthy bacterial populations.
